4.6 Article

Transcriptome Profiles of Carcinoma-in-Situ and Invasive Non-Small Cell Lung Cancer as Revealed by SAGE

期刊

PLOS ONE
卷 5, 期 2, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0009162

关键词

-

资金

  1. Genome Canada/Genome British Columbia, Canadian Cancer Society Research Institute
  2. Canadian Cancer Society Research Institute [CCS 20485]
  3. Canadian Institutes of Health Canada [MOP200113, MOP 86731]

向作者/读者索取更多资源

Background: Non-small cell lung cancer (NSCLC) presents as a progressive disease spanning precancerous, preinvasive, locally invasive, and metastatic lesions. Identification of biological pathways reflective of these progressive stages, and aberrantly expressed genes associated with these pathways, would conceivably enhance therapeutic approaches to this devastating disease. Methodology/Principal Findings: Through the construction and analysis of SAGE libraries, we have determined transcriptome profiles for preinvasive carcinoma-in-situ (CIS) and invasive squamous cell carcinoma (SCC) of the lung, and compared these with expression profiles generated from both bronchial epithelium, and precancerous metaplastic and dysplastic lesions using Ingenuity Pathway Analysis. Expression of genes associated with epidermal development, and loss of expression of genes associated with mucociliary biology, are predominant features of CIS, largely shared with precancerous lesions. Additionally, expression of genes associated with xenobiotic metabolism/detoxification is a notable feature of CIS, and is largely maintained in invasive cancer. Genes related to tissue fibrosis and acute phase immune response are characteristic of the invasive SCC phenotype. Moreover, the data presented here suggests that tissue remodeling/fibrosis is initiated at the early stages of CIS. Additionally, this study indicates that alteration in copy-number status represents a plausible mechanism for differential gene expression in CIS and invasive SCC. Conclusions/Significance: This study is the first report of large-scale expression profiling of CIS of the lung. Unbiased expression profiling of these preinvasive and invasive lesions provides a platform for further investigations into the molecular genetic events relevant to early stages of squamous NSCLC development. Additionally, up-regulated genes detected at extreme differences between CIS and invasive cancer may have potential to serve as biomarkers for early detection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer

Ryan Sun, Miao Xu, Xihao Li, Sheila Gaynor, Hufeng Zhou, Zilin Li, Yohan Bosse, Stephen Lam, Ming-Sound Tsao, Adonina Tardon, Chu Chen, Jennifer Doherty, Gary Goodman, Stig E. Bojesen, Maria T. Landi, Mattias Johansson, John K. Field, Heike Bickeboeller, H-Erich Wichmann, Angela Risch, Gadi Rennert, Suzanne Arnold, Xifeng Wu, Olle Melander, Hans Brunnstrom, Loic Le Marchand, Geoffrey Liu, Angeline Andrew, Eric Duell, Lambertus A. Kiemeney, Hongbing Shen, Aage Haugen, Mikael Johansson, Kjell Grankvist, Neil Caporaso, Penella Woll, M. Dawn Teare, Ghislaine Scelo, Yun-Chul Hong, Jian-Min Yuan, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Demetrios Albanes, Raymond Mak, David Barbie, Paul Brennan, Rayjean J. Hung, Christopher I. Amos, David C. Christiani, Xihong Lin

Summary: This study prioritizes and characterizes single nucleotide polymorphisms (SNPs) that increase the risk of squamous cell lung cancer by utilizing extensive multiomics data sources and genome-wide functional annotations. The reanalysis of data highlights the impact of SNPs from nuclear factor-kappa B signaling pathway genes and major histocompatibility complex-mediated immune responses on lung cancer. The strategies introduced in this study provide informative and systematic approaches for incorporating genome-wide annotation data in genetic association studies.

GENETIC EPIDEMIOLOGY (2021)

Article Multidisciplinary Sciences

Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers

Nhu-An Pham, Nikolina Radulovich, Emin Ibrahimov, Sebastiao N. Martins-Filho, Quan Li, Melania Pintilie, Jessica Weiss, Vibha Raghavan, Michael Cabanero, Robert E. Denroche, Julie M. Wilson, Cristiane Metran-Nascente, Ayelet Borgida, Shawn Hutchinson, Anna Dodd, Michael Begora, Dianne Chadwick, Stefano Serra, Jennifer J. Knox, Steven Gallinger, David W. Hedley, Lakshmi Muthuswamy, Ming-Sound Tsao

Summary: Patient-derived xenograft (PDX) and xenograft-derived organoid (XDO) models play a crucial role in recapitulating the genotypic and phenotypic landscape of patient cancers, specifically pancreatic ductal adenocarcinoma (PDAC). These models have shown promise in advancing research, molecular profiling of tumor models, and evaluating novel drug combination therapies.

SCIENTIFIC REPORTS (2021)

Review Oncology

Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy

Masashi Mikubo, Yoshiaki Inoue, Geoffrey Liu, Ming-Sound Tsao

Summary: A minor population of cancer cells can evade cell death from chemotherapy and targeted therapy by entering a reversible slow proliferation state known as the drug tolerant persister (DTP) state. Understanding the biology of DTP cells and developing therapeutic strategies targeting this mechanism can have significant clinical implications in overcoming cancer persistence. Emerging evidence suggests that DTP cells adapt to new environments through epigenomic modification, transcriptomic regulation, flexible energy metabolism, and interactions with the tumor microenvironment.

JOURNAL OF THORACIC ONCOLOGY (2021)

Article Oncology

Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy

Sally C. M. Lau, Christopher Poletes, Lisa W. Le, Kate M. Mackay, Aline Fusco Fares, Penelope A. Bradbury, Frances A. Shepherd, Ming Sound Tsao, Natasha B. Leighl, Geoffrey Liu, David Shultz, Adrian G. Sacher

Summary: ICIs show remarkable efficacy in the treatment of brain metastases in patients with EGFR/ALK wild-type mNSCLC, providing effective disease control. Baseline radiation plus ICIs can be considered as an effective strategy for patients with PD-L1 50% and further investigation is warranted to delay whole brain radiation therapy in this subgroup of patients.

LUNG CANCER (2021)

Article Oncology

Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges

Charu Aggarwal, Lukas Bubendorf, Wendy A. Cooper, Peter Illei, Paula Borralho Nunes, Boon-Hean Ong, Ming-Sound Tsao, Yasushi Yatabe, Keith M. Kerr

Summary: Precision medicine in non-small cell lung cancer (NSCLC) is rapidly advancing, with targeted therapies for advanced disease being developed and molecular testing becoming increasingly important. While routine molecular testing is not currently required for stage I-III disease, recent studies have shown promising results that suggest the integration of molecular testing and targeted therapy may be beneficial for these earlier stages of NSCLC in the near future.

LUNG CANCER (2021)

Editorial Material Oncology

Introduction to 2021 WHO Classification of Thoracic Tumors

Ming-Sound Tsao, Andrew G. Nicholson, Joseph J. Maleszewski, Alexander Marx, William D. Travis

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Oncology

Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors

Ku-Geng Huo, Hirotsugu Notsuda, Zhenhao Fang, Ningdi Feng Liu, Teklab Gebregiworgis, Quan Li, Nhu-An Pham, Ming Li, Ni Liu, Frances A. Shepherd, Christopher B. Marshall, Mitsuhiko Ikura, Nadeem Moghal, Ming-Sound Tsao

Summary: This study found that clinically approved EGFR TKIs can be used to treat patients with non-small cell lung cancer harboring the BRAF(G469V) mutation. Through experiments with a xenograft model and a cell line, it was confirmed that BRAF G469v is the oncogenic driver in this mutation. Structural modeling and experiments further demonstrated that BRAF(G469V) is a direct target of EGFR TKIs.

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Multidisciplinary Sciences

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors

Teklab Gebregiworgis, Yoshihito Kano, Jonathan St-Germain, Nikolina Radulovich, Molly L. Udaskin, Ahmet Mentes, Richard Huang, Betty P. K. Poon, Wenguang He, Ivette Valencia-Sama, Claire M. Robinson, Melissa Huestis, Jinmin Miao, Jen Jen Yeh, Zhong-Yin Zhang, Meredith S. Irwin, Jeffrey E. Lee, Ming-Sound Tsao, Brian Raught, Christopher B. Marshall, Michael Ohh, Mitsuhiko Ikura

Summary: This study demonstrates that KRAS Q61H mutation is not regulated by SHP2, leading to insensitivity to SHP2 inhibitors in pancreatic cancer cells. Furthermore, cancer cells with different KRAS mutations exhibit variable sensitivity to SHP2 inhibitors, potentially due to differences in regulation by GAP and GEF activities, as well as binding affinity to RAF.

NATURE COMMUNICATIONS (2021)

Article Oncology

Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma

Dalam Ly, Quan Li, Roya Navab, Cedric Zeltz, Linan Fang, Michael Cabanero, Chang-Qi Zhu, Ming-Sound Tsao, Li Zhang

Summary: Understanding how the immune system regulates the tumor microenvironment is crucial for the development of effective cancer treatments. This study reveals the adverse prognostic role of LAIR2 expression in regulatory T cells and identifies it as a potential target for future immunotherapies.

CANCERS (2022)

Article Biochemistry & Molecular Biology

Collagen Type XI Inhibits Lung Cancer-Associated Fibroblast Functions and Restrains the Integrin Binding Site Availability on Collagen Type I Matrix

Cedric Zeltz, Maryam Khalil, Roya Navab, Ming-Sound Tsao

Summary: Collagen type XI restrains collagen remodeling and cell migration mediated by cancer-associated fibroblasts (CAF), thereby limiting the invasion of lung cancer cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Oncology

Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg

Joshua C. Rosen, Adrian Sacher, Ming-Sound Tsao

Summary: KRAS(G12C) inhibitors have shown promising results in clinical trials with overall response rates ranging between 32% and 46%, and have been granted FDA approvals as second-line or later monotherapies. However, rapid tumor resistance complicates their use as a monotherapy.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Article Oncology

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer

Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein, Laura Ranich, Adam C. Smith, Cuihong Wei, Carol Cheung, Frances A. Shepherd, Geoffrey Liu, Penelope Bradbury, Prodipto Pal, Joerg Schwock, Adrian G. Sacher, Jennifer H. Law, Tracy L. Stockley, Natasha B. Leighl

Summary: In NSCLC patients, reflex testing using NGS panels can identify actionable genetic variants in the majority of cases with minimal increase in testing cost. Implementation of NGS panels is essential for the treatment of NSCLC patients as treatment paradigms continue to evolve.

CURRENT ONCOLOGY (2022)

Meeting Abstract Medicine, Research & Experimental

Reproducibility in Assessment of Invasion in Lung Adenocarcinoma with Lepidic Component: An Interobserver Concordance Study with Cytokeratin 7 Stain

Ellen Yang, Najd Alshamlan, Jessica Weiss, Michael Cabanero, Ming Tsao

LABORATORY INVESTIGATION (2022)

Meeting Abstract Immunology

Uncovering the underlying immune perturbations that determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection

Wenxi Xu, Laura M. Snell, Mengdi Guo, Giselle Boukhaled, Bethany L. Macleod, Ming Li, Michael V. Tullius, Cynthia J. Guidos, Ming-Sound Tsao, Maziar Divangahi, Marcus A. Horwitz, Jun Liu, David G. Brooks

JOURNAL OF IMMUNOLOGY (2021)

Review Oncology

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer

Barbara Melosky, Parneet Cheema, Rosalyn A. Juergens, Natasha B. Leighl, Geoffrey Liu, Paul Wheatley-Price, Adrian Sacher, Stephanie Snow, Ming-Sound Tsao, Deanna McLeod, Quincy Chu

Summary: Adjuvant treatment with EGFR inhibitors in early NSCLC has shown varying efficacy, but osimertinib has emerged as an important new option for stage II-IIIA EGFR-mutated NSCLC.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

暂无数据